A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Objective To explore long‐term safety and tolerability of anifrolumab 300 mg compared with placebo in patients with systemic lupus erythematosus (SLE) who completed a Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP) trial and enrolled in the placebo‐controlled 3‐year long‐term exte...

Full description

Saved in:

Bibliographic Details
Published in:	Arthritis & Rheumatology Vol. 75; no. 2; pp. 253 - 265
Main Authors:	Kalunian, Kenneth C., Furie, Richard, Morand, Eric F., Bruce, Ian N., Manzi, Susan, Tanaka, Yoshiya, Winthrop, Kevin, Hupka, Ihor, Zhang, Lijin (Jinny), Werther, Shanti, Abreu, Gabriel, Hultquist, Micki, Tummala, Raj, Lindholm, Catharina, Al‐Mossawi, Hussein
Format:	Journal Article
Language:	English
Published:	Boston, USA Wiley 01.02.2023 Wiley Periodicals, Inc Wiley Subscription Services, Inc
Subjects:	6.1 Pharmaceuticals Antibodies Antibodies, Monoclonal, Humanized Antibodies, Monoclonal, Humanized - adverse effects Arthritis & Rheumatology Autoimmune Disease Autoimmune diseases Biomedical and Clinical Sciences Chronic conditions Clinical Research Clinical Sciences Clinical trials Clinical Trials and Supportive Activities COVID-19 Evaluation of treatments and therapeutic interventions Exposure Full Length Glucocorticoids Health services Humanized Humans Immunology Immunosuppressive agents Infections Inflammatory and immune system Lupus Lupus Erythematosus Lupus Erythematosus, Systemic Lupus Erythematosus, Systemic - chemically induced Lupus Erythematosus, Systemic - drug therapy Malignancy Monoclonal Monoclonal antibodies Patient Safety Patients Placebos Public Health and Health Services Risk assessment Safety Systemic Systemic Lupus Erythematosus Treatment Outcome
ISSN:	2326-5191, 2326-5205, 2326-5205
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!